Back to Research Hub
Vertex Pharmaceuticals Incorporated
VRTX
$445.77+2.81 (+0.63%)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane…
StreetsValue research for Vertex Pharmaceuticals Incorporated (VRTX)
Members get the full report for Vertex Pharmaceuticals Incorporated: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.